Please provide your email address to receive an email when new articles are posted on . The complete response letter cites facility issues in denying the biosimilar. The approval process had been on ...

The FDA has accepted the supplemental biologics license application for interchangeability designation for Hadlima (adalimumab-bwwd), a biosimilar to Humira, from Organon (NYSE:OGN) and Samsung ...

Teva’s dream of a smooth summer launch for its Alvotech-partnered Humira biosimilar is in jeopardy after its Icelandic compatriot weathered a second FDA snub in less than a year. Manufacturing ...

Alvotech (NASDAQ:ALVO) shares dropped ~7% pre-market Thursday after the Iceland-based drugmaker said that the FDA declined to approve AVT02, a biosimilar candidate to AbbVie (ABBV) blockbuster ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

* ALVOTECH: FDA DEFERRING ACTION ON APPLICATION FOR AVT02, PROPOSED BIOSIMILAR TO HUMIRA, UNTIL FACILITY ASSESSMENTS CAN BE COMPLETED * ALVOTECH: CONTINUES TO WORK WITH FDA TO COORDINATE REQUIRED ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...